SELLAS Life Sciences Group Inc (SLS): Next-Year EPS Estimate 53.66%
As of 2026-11-12, SELLAS Life Sciences Group Inc (SLS) has a next-year EPS growth estimate of 53.66%. Featured in 2 EPS revision reports, most recently on 2026-08-21.
Analyst estimates for SLS have remained steady in the most recent observable window, with next-year EPS growth projected at 53.66%. Current-year growth stands at 18.00%.
What's Driving This
Analysts raised the next-year EPS growth estimate from 40.48% to 52.38% on 2026-08-12, serving as the primary structural driver behind SLS’s rise. The upgrade appears connected to SLS’s narrower Q2 loss and continued progress with SLS009 in AML, which also drew buying from JPMorgan and Stifel. Momentum has continued, with the current next-year EPS growth estimate now at 53.66%.
Generated 2026-09-09 from news as of 2026-09-09
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 53.66%
- EPS growth this year
- 18.00%
- EPS next quarter (est)
- -$0.05
- Last price
- $8.03
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-11-12 | 53.66% | 18.00% | -$0.05 | $8.03 |
| 2026-11-11 | 53.66% | 18.00% | -$0.05 | $8.42 |
| 2026-11-10 | 53.66% | 18.00% | -$0.05 | $8.37 |
| 2026-11-09 | 53.66% | 18.00% | -$0.05 | $8.58 |
| 2026-11-07 | 53.66% | 18.00% | -$0.05 | $8.42 |
| 2026-11-06 | 53.66% | 18.00% | -$0.05 | $8.42 |
| 2026-11-05 | 53.66% | 18.00% | -$0.05 | $7.88 |
| 2026-11-04 | 53.66% | 18.00% | -$0.05 | $9.14 |
| 2026-11-03 | 53.66% | 18.00% | -$0.05 | $8.87 |
| 2026-11-02 | 53.66% | 18.00% | -$0.05 | $8.55 |
| 2026-10-31 | 53.66% | 18.00% | -$0.05 | $9.68 |
| 2026-10-30 | 53.66% | 18.00% | -$0.05 | $9.68 |
| 2026-10-29 | 53.66% | 18.00% | -$0.05 | $10.15 |
| 2026-10-28 | 53.66% | 18.00% | -$0.05 | $10.38 |
| 2026-10-27 | 53.66% | 18.00% | -$0.05 | $12.17 |
| 2026-10-26 | 53.66% | 18.00% | -$0.05 | $11.34 |
| 2026-10-23 | 53.66% | 18.00% | -$0.05 | $11.54 |
| 2026-10-22 | 53.66% | 18.00% | -$0.05 | $11.35 |
| 2026-10-21 | 53.66% | 18.00% | -$0.05 | $12.14 |
| 2026-10-20 | 53.66% | 18.00% | -$0.05 | $11.98 |
| 2026-10-19 | 53.66% | 18.00% | -$0.05 | $10.49 |
| 2026-10-16 | 53.66% | 18.00% | -$0.05 | $9.98 |
| 2026-10-15 | 53.66% | 18.00% | -$0.05 | $11.34 |
| 2026-10-14 | 53.66% | 18.00% | -$0.05 | $11.88 |
| 2026-10-13 | 53.66% | 18.00% | -$0.05 | $12.41 |
| 2026-10-12 | 53.66% | 18.00% | -$0.05 | $11.93 |
| 2026-10-11 | 53.66% | 18.00% | -$0.05 | $11.65 |
| 2026-10-10 | 53.66% | 18.00% | -$0.05 | $11.65 |
| 2026-10-09 | 53.66% | 18.00% | -$0.05 | $11.65 |
| 2026-10-08 | 53.66% | 18.00% | -$0.05 | $11.26 |
Reports Featuring SLS
Recent News
- SLS Stock Logs Best Day In Over A Week: JPMorgan Buys In And Stifel Boosts Bet Ahead Of Key AML DataStocktwits
- Sellas Experimental Drug SLS009 Appears To Be Leading The CDK9 Race, Says Alliance Global Analyst Sees About 200% Upside PotentialStocktwits
- Sellas Experimental Drug SLS009 Appears To Be Leading The CDK9 Race, Says Alliance Global Analyst Sees About 200% Upside PotentialStocktwits
- SLS Stock Flat After-Hours Despite Narrower Per-Share Q2 Loss Investors Eye End Of GPS Quiet PeriodStocktwits
- SLS Stock Holds Steady After Q2 Update Investors Eye End Of GPS Quiet PeriodStocktwits
- SLS Stock Flat After-Hours Despite Narrower Per-Share Q2 Loss Investors Eye End Of GPS Quiet PeriodStocktwits
- SLS Stock Holds Steady After Q2 Update Investors Eye End Of GPS Quiet PeriodStocktwits
- SLS Stock Snaps 2-Day Slide: Sellas SLS009 AML Trial Spotlights Big Pharma Drug Combo From ABBV, RHHBY And BMYStocktwits
- Inventiva Builds Up Leadership Team Ahead of Potential CommercializationExec Edge
- These 16 stocks are a short seller's dream - likely losers no matter what the market doesMarketWatch
Screen Performance
Aggregate stats across all 2145 tickers our top-EPS-revision screen has flagged over the past 225 days.
- Median return since detection
- -2.9%
- % of tickers in the green
- 43%
- Median return on winners
- +22.8%
- Large revisions captured
- 2246
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is SELLAS Life Sciences Group Inc's next-year EPS growth estimate?▾
As of 2026-11-12, SELLAS Life Sciences Group Inc (SLS) has a next-year EPS growth estimate of 53.66%, based on analyst consensus.
What sector and industry does SELLAS Life Sciences Group Inc belong to?▾
SELLAS Life Sciences Group Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. SLS appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. SELLAS Life Sciences Group Inc (SLS) appears here because it was detected by our daily top-EPS-revision-performer screen.